

**Cited In for PMID: 26116124**

85 results

- 1 **Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.**
Weinisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ.
EJNMMI Res. 2014 Dec;4(1):63. doi: 10.1186/s13550-014-0063-1. Epub 2014 Nov 25.
PMID: 26116124 [Free PMC article](#).
- 2 **Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies.**
Zhang J, Chadha JS.
Cancers (Basel). 2024 Sep 6;16(17):3098. doi: 10.3390/cancers16173098.
PMID: 39272956 [Free PMC article](#). Review.
- 3 **PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.**
Debnath S, Zhou N, McLaughlin M, Rice S, Pillai AK, Hao G, Sun X.
Int J Mol Sci. 2022 Jan 21;23(3):1158. doi: 10.3390/ijms23031158.
PMID: 35163083 [Free PMC article](#). Review.
- 4 **Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.**
Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, Tauber R, Grogan TR, Czernin J, Rettig MB, Herrmann K, Calais J, Weber WA, Benz MR, Fendler WP, Eiber M.
J Nucl Med. 2022 Nov;63(11):1651-1658. doi: 10.2967/jnumed.121.263072. Epub 2022 Apr 14.
PMID: 35422442 [Free PMC article](#).
- 5 **Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis.**
Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, Li M, Schultze-Seemann W, Ilhan H, Fendler WP, Bartenstein P, Grosu AL, Ganswindt U, Belka C, Meyer PT, Zamboglou C.
J Nucl Med. 2019 Feb 1;60(2):227-233. doi: 10.2967/jnumed.118.212563. Epub 2018 Jul 12.
PMID: 30002108 [Free PMC article](#).
- 6 **PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [¹⁷⁷Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study.**
Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, Eiber M, Emmett L, Farolfi A, Fendler WP, Weber MM, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J.
J Nucl Med. 2023 Jul;64(7):1024-1029. doi: 10.2967/jnumed.122.265242. Epub 2023 Mar 30.
PMID: 36997329 [Free PMC article](#).
- 7 **Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.**
Van Laere C, Koole M, Deroose CM, de Voorde MV, Baete K, Cocolios TE, Duchemin C, Ooms M, Cleeren F.
Theranostics. 2024 Feb 17;14(4):1720-1743. doi: 10.7150/thno.92775. eCollection 2024.
PMID: 38389843 [Free PMC article](#). Review.
- 8 **Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer.**
Teo MY, Morris MJ.
Cancer J. 2016 Sep/Oct;22(5):347-352. doi: 10.1097/PPO.0000000000000221.
PMID: 27749329 [Free PMC article](#). Review.
- 9 **Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer.**

Ritawidya R, Wongso H, Effendi N, Pujiyanto A, Lestari W, Setiawan H, Humani TS.

Adv Pharm Bull. 2023 Nov;13(4):701-711. doi: 10.34172/apb.2023.079. Epub 2023 Apr 29.

PMID: 38022814 [Free PMC article](#). Review.

10 [The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II \(PSMA/GCPII\) in cancer and neurological disease.](#)

Evans JC, Malhotra M, Cryan JF, O'Driscoll CM.

Br J Pharmacol. 2016 Nov;173(21):3041-3079. doi: 10.1111/bph.13576. Epub 2016 Sep 23.

PMID: 27526115 [Free PMC article](#). Review.

« First

« Prev

Page 1 of 9 [Next](#) >

[Last](#) >>

FOLLOW NCBI



Connect with NLM



National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894

[Web Policies](#)
[FOIA](#)
[HHS Vulnerability Disclosure](#)

[Help](#)
[Accessibility](#)
[Careers](#)

[NLM](#) [NIH](#) [HHS](#) [USA.gov](#)